August 14 , 2026

TWSE 4746

Hope, Passion, Innovation, Sustainability

- 2026 up to July Operation Results
- Business Strategy
- Business Update

Disclaimer

This material has been prepared by Formosa Laboratories Inc. (“Formosalab”).

Any opinions expressed in this material are subject to change without notice as a result of using different assumptions. Formosalab is under no obligation to update or keep current the information contained herein. The information contained in this presentation is Formosalab’ s confidential information.

Any disclosure, copying, distribution or any action taken or omitted to be taken in reliance on it is prohibited and may be unlawful.

No representation or warranty, express or implied, is or will be made in or in relation to, and no responsibility or liability is or will be accepted by the Company as to, the accuracy or completeness of this material and any liability therefore is hereby expressly disclaimed.

Statements made in this material include forward-looking statements, which include, without limitation, statements about the issues, plans and expectations of Formosalab. Without limiting the foregoing, statements including the words “believes” , “anticipates” , “plans” , “expects” and similar expressions are also forward-looking statements. Forward-looking statements reflect, among other

things, management’ s plans and objectives for future operations, current views with respect to future events and future economic performances and projections of various financial items.

These forwardlooking statements involve known and unknown risks, uncertainties and other factors which may cause actual results to differ materially from those implied by such forward-looking statements.

Operation Results

Consolidated Revenues 2026 up to July YoY -7%



Million NTD

Revenues 2026 up to July YoY -7%

	Million NTD	YoY
Polymers	879	-8%
Vit. D Derivatives	509	21%
CDMO	371	44%
Steroids	242	-34%
Respiratory Agents	148	-52%
Inflammation	147	104%
Others	267	-30%
Total	**2,563**	**-7%**

Product Category



2026 1H Profitability

EPS	NTD	0.04
BV per share	NTD	61.75



2025Q2~2026Q2 Profitability

Business Strategy

Integrated RD and Manufacturing

- High quality GMP manufacturing
- Supply chain management
- Effective output to fulfill demand

- DS to DP one stop service
- ADC
- Peptide



- Formulation development
- Clinical and commercial manufacturing
- Product development and license-out

Diversified Alliance to Explore Business Opportunity



Expand Oversee Footprint and Market

Key Business

Key API Products

- Improve throughput
- Expand manufacture capacity
- Stable supply chain

Highlight

- **Polymer**: Market share remains leading.
- **Vitamin D**: New products have been gradually commercialized, contributing to revenue.
- **Steroid** : Shipments remain growing.
- **Inflammation**: stable contributing to revenue.

Comprehensive CDMO Service-One Stop Shop

Research → CMC Development → API/DS Manufacturing → Injectable Manufacturing → Labelling/ Packaging/ Logistics

- Stable CMO supply to originator in Japan, Europe, Australia, and US. New projects under discussion.
- Formosa stably expands North American CDMO business. Few clinical material manufacturing stage have completed. Scale-up manufacturing is ongoing and discussing future demand. New projects under discussion.
- Formosa Japan is actively putting resources to expand Japanese CDMO business. New projects ongoing.
- Provide peptide development RD services to big pharma/
- Injectable CDMO covers clinical and commercial stages.

Once stop ADC services

Service scope

- Linker-payload, Bioconjugation, and process development
- ADC candidate screening platform
- Scale-up manufacturing. ADC-DS new line completes validation. The new line can support upto commercial scale supply
- Comprehensive analytic services

ADC CDMO highlight

- Clients include US, Europe, Ausralia, and Taiwan.
- European client enters Phase I/II trial. Patient enrollment is ongoing. Scale-up manufacturing is ongoing. New ADC project kicked off and new candidates screening ongoing.
- Three one-stop and eight candidates projects are ongoing.
- Synchem-Formosa is expanding laboratories and early stage bio-conjugation line to fulfill North American CDMO market demand.
- Signed MOU with few biotech companies to offer diverse ADC platform CDMO services. Few potential projects under discussion.

Injectable Plant Status

- Authority inspection is ongoing
  - Cytotoxic line
    - TFDA: 2022Q2 completed
    - FDA: passed first FDA on-site GMP inspection held in July 2024
    - EMA: passed first EMA on-site GMP inspection held in May 2025
    - TMMDA: completed Turkish EMA on-site GMP inspection in September 2025
  - General line
    - TFDA: 2024/08 completed inspection. Receive GMP certificate by 2025Q2.
- Feasible for biologic and chemical drug product in liquid and lyophilization products from lab-scale, clinical trial and commercial supply.
- Work with medical device company as alliance for product development.

Self-development Injectable Products

◆ Eribulin Injectable

(Global market size USD 370 million, US Market USD 130 million, EU market USD 80 million, TW market NTD 450 million)

Territory	Status
Taiwan	Hospital listing keeps going.
Turkey	Licensing agreement signed, registration ongoing.
EU	Licensing agreement signed. Approval in 10 EU countries.
US	Licensing agreement signed. Approval and launch on market.
Emerging market	- Hong Kong and Pakistan agreement signed - Saudi Arabia and Algeria licensing agreement signed.
Canada	Under discussion
LATAM	Under discussion

Self-development Injectable Products

Other self-development injectable products are ongoing
- Anemia
- Jointly develop the TLX-054 injectable with Easywell.
- GLP-1 Products

  Semaglutide injection is the first product under development.
  The estimated global market size is approximately:
  Ozempic: USD 19 billion*
  Wegovy: USD 12 billion*
- Formulation development is currently in progress
- Commercial production lines and assembly lines are under construction
- Global partner

* 2025 Novo Nordisk annual report released

Q & A